Paris exchange. Sector: Healthcare. Industry: Medical Instruments & Supplies. Location France, Aubagne.

Sartorius Stedim Biotech S.A. [DIM.PAFrance

351.6USD6.5 (+1.85%)

• At close Thu Oct 06 2022

31,720,516,817 USD
MARKET CAP
78.933
PE
0.574
BETA (5y)
4.310
EPS

profit

528%

for 5 years

profit

265%

for 3 years

profit

117%

for 2 years

profit

2%

for 1 year

profit

-9%

for this year

About Sartorius Stedim Biotech S.A.

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Sartorius offers solutions for the biopharmaceutical industry and laboratories, from drug discovery and development to production platforms for biomanufacturing.

Sartorius Stedim Biotech S.A.
https://www.sartorius.com
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.